1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.08.1133
Abstract: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: AstraZeneca; Research grant/Funding (self): Boehringer Ingelheim. A.B. El-Khoueiry: Honoraria (self), Advisory/Consultancy: CytomX Therapeutics; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy:… read more here.
Keywords: research grant; advisory consultancy; self advisory; honoraria self ... See more keywords
349P Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.10.343
Abstract: sponsored partly by Chugai Pharmaceutical Co., Ltd.: Chugai; Research grant/Funding (self): Sanofi. M. Yanagita: Honoraria (self): Chugai; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Tanabe Mitsubishi; Research grant/… read more here.
Keywords: research grant; grant funding; funding institution;
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2021.03.111
Abstract: Background: CDK4-6 inhibitors are now considered the standard of care for advanced ER-positive HER2-negative advanced breast cancer (ABC) in combination with endocrine therapy (ET). During the first wave of the COVID-19 pandemic, clinicians were uncertain… read more here.
Keywords: funding institution; research grant; grant funding;
The Impact of False Investigators on Grant Funding
Sign Up to like & getrecommendations! Published in 2021 at "Research Policy"
DOI: 10.1016/j.respol.2021.104366
Abstract: Abstract False investigators are researchers who have been listed on grant proposals as part of a research team even though there is no expectation that they will contribute to the research effort. Their use seems… read more here.
Keywords: research; impact false; grant funding; investigators grant ... See more keywords
The state of K2R grant funding by cancer type from the National Cancer Institute
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)01233-6
Abstract: Objectives: Given that K grant funding secured in early career correlates with success in achieving R funding, we aim to describe the state of K and R funding by cancer type through time, hypothesizing that… read more here.
Keywords: cancer sites; grant funding; funding; cancer ... See more keywords
GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz238.027
Abstract: Abstract Background EPHA2 tyrosine kinase receptor is implicated in tumor progression, stemness phenotype and resistance to treatment in a wide range of cancers. We investigated the effects of GLPG1790, a new selective Eph receptor inhibitor,… read more here.
Keywords: funding institution; research grant; grant funding; institution ... See more keywords
Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz239.067
Abstract: Abstract Background Introduction of checkpoint inhibitors (anti PD-1/PD-L1) have resulted in improved survival for bladder cancer patients, however, only a subset will benefit. The utility of PD-L1 expression as a prognostic or predictive biomarker is… read more here.
Keywords: funding institution; research grant; research; grant funding ... See more keywords
Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz240.010
Abstract: Abstract Background Neoadjuvant treatment of triple negative breast cancer (TNBC) in general implies different chemotherapy regimens administered in sequence. PARP inhibitors like olaparib have revealed clinical benefit in TNBC harboring BRCA germline mutations, but were… read more here.
Keywords: grant funding; research grant; honoraria self; honoraria ... See more keywords
Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz240.110
Abstract: Abstract Background Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) is safe and demonstrated modest activity in H-resistant HER2-positive (HER2+) metastatic… read more here.
Keywords: research grant; grant funding; consultancy; advisory consultancy ... See more keywords
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz240.112
Abstract: Abstract Background Early stage triple negative breast cancer (TNBC) is associated with a high risk of distant relapse. Because TNBC does not currently have specific targeted agents approved for use in the early setting it… read more here.
Keywords: research; research grant; grant funding; roche genentech ... See more keywords
Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz241.004
Abstract: Abstract Background About 20% of breast cancer (BC) patients do not attain tamoxifen’s (TAM) active metabolite endoxifen (ENDX) target concentrations when receiving 20 mg TAM once daily (q.d.). Thus, individualised dosing of up to 120 mg TAM… read more here.
Keywords: funding institution; research grant; research; grant funding ... See more keywords